BLACK DIAMOND THERAPEUTICS, INC. (BDTX) Current Ratio
- Current ratio · latest quarter: Value 7.28×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 7.28× | Current assets / current liabilities. $115.39M ÷ $15.84M ≈ 7.28× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 115.39M USD | Assets, Current |
| Current obligations | 15.84M USD | Liabilities, Current |
| Cash and equivalents | 19.19M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 91.31M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 1.40M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $115.39M | $15.84M | $19.19M | $91.31M | (m) | (m) | $1.40M | (m) | 7.28× |
| 2026-03-31 | $122.97M | $14.53M | $30.07M | $88.19M | (m) | (m) | $2.97M | (m) | 8.46× |
| 2025-12-31 | $132.44M | $15.73M | $20.99M | $107.66M | (m) | (m) | $579.00K | (m) | 8.42× |
| 2025-09-30 | $138.99M | $15.54M | $30.86M | $104.64M | (m) | (m) | $975.00K | (m) | 8.94× |
| 2025-06-30 | $146.73M | $16.80M | $29.99M | $112.84M | (m) | (m) | $771.00K | (m) | 8.73× |
| 2025-03-31 | $155.68M | $16.85M | $98.42M | $53.98M | (m) | (m) | $2.63M | (m) | 9.24× |
| 2024-12-31 | $101.18M | $20.57M | $36.44M | $62.14M | (m) | (m) | $4.01M | (m) | 4.92× |
| 2024-09-30 | $115.54M | $20.80M | $23.43M | $89.26M | (m) | (m) | $1.97M | (m) | 5.55× |
| 2024-06-30 | $126.75M | $18.44M | $32.81M | $90.16M | (m) | (m) | $763.00K | (m) | 6.87× |
| 2024-03-31 | $118.81M | $16.85M | $25.42M | $89.78M | (m) | (m) | $1.18M | (m) | 7.05× |
| 2023-12-31 | $134.03M | $19.65M | $56.22M | $75.18M | (m) | (m) | $2.32M | (m) | 6.82× |
| 2023-09-30 | $147.05M | $15.07M | $57.98M | $86.28M | (m) | (m) | $694.00K | (m) | 9.76× |
| 2023-06-30 | $92.99M | $13.90M | $41.89M | $47.64M | (m) | (m) | $2.74M | (m) | 6.69× |
| 2023-03-31 | $107.98M | $12.85M | $39.14M | $64.22M | (m) | (m) | $3.05M | (m) | 8.40× |
| 2022-12-31 | $127.71M | $15.26M | $34.31M | $88.49M | (m) | (m) | $1.88M | (m) | 8.37× |
| 2022-09-30 | $150.98M | $21.14M | $53.96M | $90.22M | (m) | (m) | $5.76M | (m) | 7.14× |
| 2022-06-30 | $168.56M | $19.71M | $55.88M | $105.01M | (m) | (m) | $2.22M | (m) | 8.55× |
| 2022-03-31 | $188.30M | $19.47M | $54.08M | $125.66M | (m) | (m) | $1.88M | (m) | 9.67× |
| 2021-12-31 | $215.70M | $23.64M | $65.80M | $143.99M | (m) | (m) | $4.11M | (m) | 9.12× |
| 2021-09-30 | $241.55M | $26.36M | $46.60M | $188.41M | (m) | (m) | $4.86M | (m) | 9.16× |
| 2021-06-30 | $270.95M | $23.49M | $37.32M | $226.15M | (m) | (m) | $5.03M | (m) | 11.54× |
| 2021-03-31 | $297.35M | $18.70M | $14.11M | $275.95M | (m) | (m) | $4.62M | (m) | 15.90× |
| 2020-12-31 | $319.55M | $14.22M | $34.60M | $280.46M | (m) | (m) | $2.54M | (m) | 22.48× |
| 2020-09-30 | $336.43M | $11.34M | $56.20M | $276.88M | (m) | (m) | $2.93M | (m) | 29.66× |
| 2020-06-30 | $208.25M | $6.14M | $63.98M | $140.50M | (m) | (m) | $45.00K | (m) | 33.92× |
| 2020-03-31 | $362.09M | $7.30M | $357.19M | (m) | (m) | (m) | $3.80M | (m) | 49.60× |
| 2019-12-31 | $155.71M | $4.86M | $154.67M | $0.00 | (m) | (m) | $1.96M | (m) | 32.02× |
| 2018-12-31 | $51.68M | $2.58M | $51.66M | (m) | (m) | (m) | $416.00K | (m) | 20.07× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |